Dyadic to Present at Upcoming Industry and Investor Events in November

by dyadic | Nov 7, 2022 | Press Releases

JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

by dyadic | Oct 27, 2022 | Press Releases

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative...

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

by dyadic | Oct 27, 2022 | Press Releases

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative...

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

by dyadic | Oct 4, 2022 | Press Releases

JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...

Dyadic Updates Market on Recent Scientific Achievements

by dyadic | Sep 13, 2022 | Press Releases

JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...